Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2

Skin and skin structure infections: treatment with newer generation fluoroquinolones

Authors Philip Giordano, Kurt Weber, Gail Gesin, Jason Kubert

Published 15 May 2007 Volume 2007:3(2) Pages 309—317

Philip Giordano1, Kurt Weber1, Gail Gesin2, Jason Kubert1

1Department of Emergency Medicine; 2Department of Pharmacy, Orlando Regional Medical Center, Orlando, Florida, USA

Abstract: Skin and skin structure infections (SSSI) are an emerging issue in healthcare. They are responsible for increasing heathcare utilization, both in hospitalizations and intravenous antibiotic use. SSSI are caused by an evolving variety of pathogens, including Gram-positive, Gram-negative, and anaerobic bacteria. In combination with mounting resistance patterns, this diverse range of bacteria mandate empiric broad-spectrum antibiotic coverage. Historically, cephalosporins and penicillins have been the mainstay of treatment, but recent data suggest newer generation fluoroquinolones are being used with increasing frequency. In 2005, moxifloxacin joined gatifloxacin and levofloxacin as newer generation fluoroquionolones with Food and Drug Administration indications for SSSIs. Even within this group there exist subtle differences that impact optimal management. This paper offers the clinician a comparative review of the antimicrobial spectrum, pharmacodynamics, pharmacokinetics, and clinical efficacy data to support the appropriate use of fluoroquinolones in SSSIs.

Keywords: Uncomplicated skin and skin structure infections, complicated skin and skin structure infections, fluoroquinolone, moxifloxacin, gatifloxacin, levofloxacin

Download Article [PDF] 

Readers of this article also read:

Risk factors for amyotrophic lateral sclerosis

Ingre C, Roos PM, Piehl F, Kamel F, Fang F

Clinical Epidemiology 2015, 7:181-193

Published Date: 12 February 2015

Photo activation of HPPH encapsulated in “Pocket” liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts

Sine J, Urban C, Thayer D, Charron H, Valim N, Tata DB, Schiff R, Blumenthal R, Joshi A, Puri A

International Journal of Nanomedicine 2015, 10:125-145

Published Date: 19 December 2014

A case of mitochondrial cardiomyopathy with restrictive transmitral filling pattern

Otsui K, Inoue N, Tamagawa A, Onishi K

International Medical Case Reports Journal 2012, 5:19-22

Published Date: 13 April 2012

Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus-eluting stent in a consecutive cohort of patients at a tertiary medical center

Shammas NW, Shammas GA , Nader E, Jerin M, Mrad L, Marogil P, Henn C, Dvorak A, Chintalapani A, Meriner S

Vascular Health and Risk Management 2012, 8:205-211

Published Date: 11 April 2012

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Therapeutics and Clinical Risk Management 2007, 3:999-1001

Published Date: 15 January 2008

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results

Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Carlo Lombardi, et al

Therapeutics and Clinical Risk Management 2007, 3:569-578

Published Date: 15 September 2007

Infliximab in the treatment of Crohn’s disease

Gilberto Poggioli, Silvio Laureti, Massimo Campieri, Filippo Pierangeli, Paolo Gionchetti, et al

Therapeutics and Clinical Risk Management 2007, 3:301-308

Published Date: 15 May 2007

Marked effect of milnacipran combined with olanzapine for a delusional depressive patient

Yuka Sugawara, Hisashi Higuchi, Keizo Yoshida, Tetsuo Shimizu

Neuropsychiatric Disease and Treatment 2005, 1:373-374

Published Date: 15 December 2005